Status:
COMPLETED
Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
Lead Sponsor:
University Hospital Tuebingen
Collaborating Sponsors:
German Research Foundation
Conditions:
Malignant Melanoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of the vaccination protocol is to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen.
Detailed Description
vaccination protocol to induce clinically specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigens. Half of patients is tr...
Eligibility Criteria
Inclusion
- malignant melanoma stage III/IV
- fresh frozen tumor tissue available
- informed consent given
- Karnofsky \>= 70%
Exclusion
- brain metastasis
- parallel chemotherapy
- systemic treatment with glucocorticoids
- other malignancies
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00204516
Start Date
April 1 2007
End Date
December 1 2012
Last Update
January 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, University of Tuebingen
Tübingen, Germany, 72076